Underestimation of Cirrhosis-Related Mortality in the Medicare Eligible Population, 1999–2018

Griffin, Connor; Agbim, Uchenna; Ramani, Ananthakrishnan; Shankar, Nagasri; Kanwal, Fasiha; Asrani, Sumeet K.

doi:10.1016/j.cgh.2021.10.036

Cited by 12 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2020, approximately 905,700 people were diagnosed with liver cancer, and approximately 830,200 people died from liver cancer worldwide 9 . Although the burden of liver disease is increasing, liver disease‐related mortality may be underestimated 10 . Surveys have shown that approximately 2 million people die each year due to liver disease, accounting for 4% of all deaths 8,11 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The role of anoctamin 1 in liver disease

Li,

Wang,

Zhang

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

Liver diseases include all types of viral hepatitis, alcoholic liver disease (ALD), nonalcoholic fatty liver disease (NAFLD), cirrhosis, liver failure (LF) and hepatocellular carcinoma (HCC). Liver disease is now one of the leading causes of disease and death worldwide, which compels us to better understand the mechanisms involved in the development of liver diseases. Anoctamin 1 (ANO1), a calcium‐activated chloride channel (CaCC), plays an important role in epithelial cell secretion, proliferation and migration. ANO1 plays a key role in transcriptional regulation as well as in many signalling pathways. It is involved in the genesis, development, progression and/or metastasis of several tumours and other diseases including liver diseases. This paper reviews the role and molecular mechanisms of ANO1 in the development of various liver diseases, aiming to provide a reference for further research on the role of ANO1 in liver diseases and to contribute to the improvement of therapeutic strategies for liver diseases by regulating ANO1.

show abstract

Section: Introductionmentioning

confidence: 99%

“… 9 Although the burden of liver disease is increasing, liver disease‐related mortality may be underestimated. 10 Surveys have shown that approximately 2 million people die each year due to liver disease, accounting for 4% of all deaths. 8 , 11 Liver diseases have become one of the leading causes of disease and death worldwide.…”

Section: Introductionmentioning

confidence: 99%

The role of anoctamin 1 in liver disease

Li,

Wang,

Zhang

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…[ 2 ] However, it may be underestimated. [ 3 ] Being the 15 th leading cause of disability-adjusted life-years (DALYs) globally, the end-stage liver disease, cirrhosis has a major impact on global health especially in the younger population aged 25 to 49 years. [ 2 ] CLDs and cirrhosis have a huge financial impact and in the last 20 years, the total financial burden due to inpatient care for liver diseases in the US has increased by 4%.…”

Section: Introductionmentioning

confidence: 99%

Preventive hepatology at AIIMS Rishikesh: Delivering comprehensive and integrated care for liver diseases in Northern state of India

Bhadoria,

Saxena,

Pandey

et al. 2024

Journal of Family Medicine and Primary Care

View full text Add to dashboard Cite

Globally, liver diseases accounts for 4% of all deaths. Annually, over 2 million deaths occur due to preventable causes of chronic liver diseases and liver cancer like fatty liver diseases (alcoholic or non alcoholic) and viral hepatitis B and C. The burden of chronic liver diseases are increasing, and the epidemiology and demographics of people affected by these diseases are changing. Policy changes, vaccination, screening, lifestyle changes and public health awareness is the key to curb down liver disaeses. To achieve the ultimate goal of reducing mortality and linkage to care for those who need specialized care for liver disease, it is vital to have dedicated preventive hepatology clinics in sync with existing liver or gastroenterology clinics at tertary care level.

show abstract

“…Liver diseases take over 2 million lives annually, which accounts for 4% of all deaths worldwide 1 and ranks liver disease as the 11th leading cause of death. 2 OLT has been proven life-saving and is considered gold standard for patients with liver-based metabolic disorders and end-stage liver failure. 3 However, there is a huge gap between the number of patients on the waiting list and the number of donor liver organs.…”

Section: Introductionmentioning

confidence: 99%

Hepatocyte transplantation: The progress and the challenges

Sun,

Yuan,

et al. 2023

Hepatology Communications

View full text Add to dashboard Cite

Numerous studies have shown that hepatocyte transplantation is a promising approach for liver diseases, such as liver-based metabolic diseases and acute liver failure. However, it lacks strong evidence to support the long-term therapeutic effects of hepatocyte transplantation in clinical practice. Currently, major hurdles include availability of quality-assured hepatocytes, efficient engraftment and repopulation, and effective immunosuppressive regimens. Notably, cell sources have been advanced recently by expanding primary human hepatocytes by means of dedifferentiation in vitro. Moreover, the transplantation efficiency was remarkably improved by the established preparative hepatic irradiation in combination with hepatic mitogenic stimuli regimens. Finally, immunosuppression drugs, including glucocorticoid and inhibitors for co-stimulating signals of T cell activation, were proposed to prevent innate and adaptive immune rejection of allografted hepatocytes. Despite remarkable progress, further studies are required to improve in vitro cell expansion technology, develop clinically feasible preconditioning regimens, and further optimize immunosuppression regimens or establish ex vivo gene correction-based autologous hepatocyte transplantation.

show abstract

Underestimation of Cirrhosis-Related Mortality in the Medicare Eligible Population, 1999–2018

Cited by 12 publications

References 8 publications

The role of anoctamin 1 in liver disease

The role of anoctamin 1 in liver disease

Preventive hepatology at AIIMS Rishikesh: Delivering comprehensive and integrated care for liver diseases in Northern state of India

Hepatocyte transplantation: The progress and the challenges

Contact Info

Product

Resources

About